Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioMarin Pharmaceutical Inc. - Common Stock (NQ:BMRN)

51.80 +0.03 (+0.06%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 17, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,648,585
Open	52.05
Bid (Size)	51.60 (500)
Ask (Size)	54.42 (400)
Prev. Close	51.77
Today's Range	51.67 - 52.41
52wk Range	50.76 - 73.51
Shares Outstanding	183,352,255
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

1 Oversold Stock Primed to Rebound and 2 That Underwhelm

December 15, 2025

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling...

Via StockStory

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

December 08, 2025

BioMarin Pharmaceutical (BMRN) presents a compelling value investment case, trading at a significant discount to its biotech peers while showing strong profitability, financial health, and growth...

Via Chartmill

Performance

YTD	-22.1%	-22.1%
1 Month	-4.9%	-4.9%
3 Month	-4.7%	-4.7%
6 Month	-6.2%	-6.2%
1 Year	-22.9%	-22.9%

More News

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

Via The Motley Fool

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

December 03, 2025

Via The Motley Fool

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Via The Motley Fool

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

Via MarketMinute

2 Reasons to Like BMRN and 1 to Stay Skeptical

November 24, 2025

Via StockStory

Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks

November 23, 2025

Via StockStory

AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

November 21, 2025

Via StockStory

BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?

November 20, 2025

Via StockStory

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗

November 20, 2025

Via The Motley Fool

The Tech Tsunami: How Breakthroughs in AI, Quantum, and Green Energy Are Reshaping the Stock Market

November 14, 2025

Via MarketMinute

1 Safe-and-Steady Stock on Our Watchlist and 2 We Question

November 12, 2025

Via StockStory

Viatris, Oscar Health, BioMarin Pharmaceutical, QuidelOrtho, and Bausch + Lomb Stocks Trade Up, What You Need To Know

November 11, 2025

Via StockStory

3 Cash-Producing Stocks with Promising Prospects

November 09, 2025

Via StockStory

This Zimmer Biomet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday ↗

November 06, 2025

Via Benzinga

BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) Presents a Compelling Value Investment Case ↗

November 05, 2025

Via Chartmill

The 5 Most Interesting Analyst Questions From BioMarin Pharmaceutical’s Q3 Earnings Call

November 03, 2025

Via StockStory

Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday ↗

October 28, 2025

Via The Motley Fool

Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today

October 28, 2025

Via StockStory

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings ↗

October 28, 2025

Via Benzinga

BMRN Q3 Deep Dive: Product Expansion and Portfolio Shifts Define Outlook

October 28, 2025

Via StockStory

BioMarin (BMRN) Q3 2025 Earnings Call Transcript ↗

October 27, 2025

Via The Motley Fool

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Reports Mixed Q3 2025 Results with Revenue Growth but Earnings Miss ↗

October 27, 2025

Via Chartmill

BioMarin Pharmaceutical (NASDAQ:BMRN) Posts Q3 Sales In Line With Estimates

October 27, 2025

Via StockStory

Frequently Asked Questions

Is BioMarin Pharmaceutical Inc. - Common Stock publicly traded?

Yes, BioMarin Pharmaceutical Inc. - Common Stock is publicly traded.

What exchange does BioMarin Pharmaceutical Inc. - Common Stock trade on?

BioMarin Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock?

The ticker symbol for BioMarin Pharmaceutical Inc. - Common Stock is BMRN on the Nasdaq Stock Market

What is the current price of BioMarin Pharmaceutical Inc. - Common Stock?

The current price of BioMarin Pharmaceutical Inc. - Common Stock is 51.80

When was BioMarin Pharmaceutical Inc. - Common Stock last traded?

The last trade of BioMarin Pharmaceutical Inc. - Common Stock was at 12/17/25 04:00 PM ET

What is the market capitalization of BioMarin Pharmaceutical Inc. - Common Stock?

The market capitalization of BioMarin Pharmaceutical Inc. - Common Stock is 9.50B

How many shares of BioMarin Pharmaceutical Inc. - Common Stock are outstanding?

BioMarin Pharmaceutical Inc. - Common Stock has 9B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.